Tuesday, September 15, 2026

Hanwha’s 2 Billion USD MRIV Contract: What to Expect from the Golden Defender

Philly Shipyard wins a $2 billion contract to build Missile Range Instrumentation Vessels for the U.S. Missile Defense Agency, enhancing defense capabilities.

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Kim Jong Un Calls for Front-Line Reinforcement and Military Restructuring at Commanders Meeting

Kim Jong Un emphasizes military restructuring and deterrence during a meeting with commanders, aiming to strengthen North Korea's military capabilities.

Health

Celltrion Submits U.S. Phase 4 IND for High-Dose 240 mg Zymfentra

Celltrion has submitted a U.S. Phase 4 trial application to support the use of a higher 240 mg dose of Zymfentra, aiming to expand personalized dosing options and strengthen the drug's position in the U.S. market.

Blood Proteins May Offer Clues to Alzheimer’s Antibody Treatment Benefits and Side-Effect Risks

A South Korean study found that blood levels of complement proteins C1q and C3 may help predict amyloid reduction and ARIA risk in patients receiving lecanemab, though larger studies are needed.

Pentrym Confirms Combination Benefits With Existing Cancer Drugs, Targets “False Resistance”

Pentrym is testing whether targeting the tumor microenvironment alongside existing cancer drugs can overcome “false resistance” and improve treatment effectiveness.

YH42946: The Promising HER2 Targeted Oral Treatment Set to Transform Cancer Care in 2026

Yuhan Corporation will reveal early results of its oral HER2-targeted therapy candidate 'YH42946' in clinical trials by year-end.

SK Biopharm Achieves MSCI ESG AAA Rating for 3rd Consecutive Year: What It Means for the Pharma Industry

SK Biopharm has achieved the highest AAA rating in MSCI's ESG evaluation for three consecutive years.
Latest

Revolutionary Blood Test for Colorectal Cancer: 90.4% Accuracy Using AI Technology

A domestic study reveals that blood tests can accurately diagnose colorectal cancer with high precision.

Discover Osteo Signal: The AI Solution Revolutionizing Osteoporosis Screening in South Korea

Daewoong Pharmaceutical signs a contract with Promedius for the domestic sales and promotion of the AI osteoporosis screening solution, Osteo Signal.

2026 Breakthrough: How CIK Cell Therapy Aims to Prevent Relapse in High-Risk DLBCL Patients

Clinical research on cell therapy for high-risk diffuse large B-cell lymphoma begins, despite the risk of relapse in complete remission.

JLK Partners with Takeyama: What This Means for AI Stroke Solutions in Japan’s Medical Market

JLK, a medical AI company, partners with Takeyama to expand its distribution network in Japan, enhancing local presence.

HLB Therapeutics’ RGN-259: What to Expect from the Upcoming Topline Results in November 2026?

HLB Therapeutics completed the last patient visit for its RGN-259 treatment in the global Phase 3 trial for neurotrophic keratitis.

In Vivo CAR-T Breakthrough: Abclon and Strike Pharma’s 1 Million EUR Eurostars Project

Abclon's CAR-T therapy project with Strike Pharma has been selected for the Eurostars international tech development program.

How DongKoo Bio & Pharma Maintains Its Dermatology Dominance While Expanding into New Fields

DongKoo Bio & Pharma expands its business into specialized medicine markets, leveraging its prescription competitiveness in dermatology and urology.

Wave 2026: How Wontech is Revolutionizing Aesthetic Medicine in Indonesia and Australia

Wontech hosts global brand events Wave in Indonesia and Australia to expand its overseas medical network and market presence.

Cognitive Training Revolution: Emocog’s Cogthera Surpasses 2000 Prescriptions in Just 12 Weeks

Emocog's digital therapy device Cogthera surpasses 2,000 prescriptions, indicating its successful integration into healthcare for elderly patients.

Why Galux is the Only Korean Bio-Tech Company on Forbes’ 2026 Asia’s 100 Most Promising Companies List?

Galaxy has been named one of Forbes' '100 Asian Companies to Watch in 2026', the only bio-healthcare firm among 9 Korean selections.

Revolutionizing Obesity Treatment: Hanmi Pharmaceutical’s Digital Fusion Drug EPPE Launching in 2026

Hanmi Pharmaceutical is developing digital therapeutics by combining obesity treatment 'Efe' with digital technology.

Revolutionary Cancer Drug Penitrium Shows Promise in Restoring Chemotherapy Effectiveness

Pennitrium Bioscience has confirmed the potential of a new drug candidate to enhance the effectiveness of existing cancer treatments.

FDA Designates BAL0891 as Rare Drug for Acute Myeloid Leukemia: What This Means for Cancer Treatment in Asia

Shinlajen's cancer drug candidate 'BAL0891' receives rare disease designation for acute myeloid leukemia from the FDA.

Revolutionizing Cardiovascular Care: How Quantum Computing is Transforming Blood Flow Analysis in 2026

Seoul St. Mary's Hospital develops technology using quantum computing to analyze blood flow in cardiovascular patients quickly and precisely.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.